Discover how Vertex Pharmaceuticals achieved 12% Q2 2025 revenue growth with new launches like ALYFTREK, CASGEVY, & JOURNAVX.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended ...

Vertex beats second-quarter earnings and revenue estimates, but shares slide as pain drug VX-993 misses study goal.

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

I think that's the case with Vertex. Here are seven reasons why Vertex is a no-brainer stock to buy on the dip.

Vertex Pharmaceuticals beat Wall Street estimates for quarterly results on Monday, helped by demand for its new cystic ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...

In connection with earnings, Vertex announced topline results from the Phase 2 study evaluating the safety and efficacy of VX ...

Discover Q2 2025 highlights from Royalty Pharma (RPRX): double-digit growth, raised guidance, a $2B partnership, efficient cost structure, & ...

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

What Happened: SACHS's recent move, as outlined in a Form 4 filing with the U.S. Securities and Exchange Commission on Thursday, involves purchasing 5,000 shares of Vertex Pharmaceuticals. The total ...

The Dow Jones Industrial Average rose 585.4 points, or 1.34%, at the open to 44173.64. The S&P 500 rose 91.93 points, or 1.47 ...